BridgeMD
Role in GVHD prophylaxis of Vitamin D in patients undergoing allogeneic transplantation of stem cells. Phase II Pilot Study
EU CTIS ID: 2024-518738-97-00
What this study is testing
Evaluation of the effectiveness of vitamin D on the degree si severity of acute and chronic GvHD
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - Patients aged > 18 years. Male and female - Diagnosis of any oncohematologic disease with transplant indication, also allowed patients not in clinical response - Patients undergoing allogeneic stem cell transplantation regardless of conditioning regimen and HSC source - Ability to sign informed consent
You likely can't join if
- - Transplantation from T-depleted or T-selected product; - Documented intolerance to the drug or any of its excipients; - Ongoing vitamin D therapy for any medical condition; -Hypercalcemia, hypercalciuria, kidney stones, renal failure; - Age < 18 years - Subjects who are not deemed legally capable of consent. - In the case of female: sex pregnancy and/or lactation.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.